Epigenesis Pharmaceuticals

Epigenesis Pharmaceuticals is a biotechnology company focused on pioneering gene-editing technologies to facilitate advanced genetic research and therapeutic development. Founded in 1995 in the United States, Epigenesis Pharmaceuticals specializes in gene-editing solutions aimed at addressing genetic disorders and enhancing agricultural productivity. The company has undergone strategic pivots to focus on biotechnological applications. The latest funding round raised USD 23.

00 mn, led by Care Capital, with participation from investors including Boston Millennia Partners, Merrill Lynch Ventures, and others. This funding supports ongoing innovations and market expansions. Epigenesis specializes in innovative biotechnological solutions aimed at advancing genetic research and therapeutic development. The company's core offerings center around proprietary gene-editing technologies that enable precise modifications at the genetic level, addressing various genetic disorders and enhancing agricultural productivity.

Their products cater to a diverse clientele, including research institutions, pharmaceutical companies, and agricultural firms, who utilize these advanced tools for applications ranging from drug discovery to crop enhancement. With a focus on markets in North America, Europe, and Asia, Epigenesis' technologies are positioned to meet the needs of an expanding global customer base interested in harnessing the potential of genomics to solve pressing health and food security challenges. Epigenesis generates revenue through a structured model that includes partnerships and licensing agreements with its clients. The company engages in B2B transactions, primarily collaborating with pharmaceutical and agricultural companies that require access to its gene-editing technologies for research and development purposes.

Revenue is derived from various agreements, including milestone payments and royalties associated with the commercialization of patented solutions. Specific pricing plans for these services are tailored based on the scopes of the projects and the nature of the collaboration, ensuring that clients receive customized solutions that align with their strategic objectives. Notable offerings, such as their flagship gene-editing platform, serve as essential tools in these transactions, reinforcing Epigenesis' position in the biotechnological landscape. Epigenesis Pharmaceuticals plans to leverage the recent funding of USD 23.

00 mn to enhance its research and development efforts, focusing on launching new gene-editing products designed to address specific genetic disorders. The company is targeting expansion into European and Asian markets by the end of 2024, aiming to increase its global footprint. This growth strategy includes strengthening existing partnerships and establishing new collaborations, particularly in regions with emerging biotechnological needs.